Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Astellas And AstraZeneca To Launch Symbicort Turbuhaler

This article was originally published in PharmAsia News

Executive Summary

Astellas and AstraZeneca announced they will launch Symbicort Turbuhaler (budesonide/formoterol) for adult bronchial asthma patients in Japan next January

Astellas and AstraZeneca announced they will launch Symbicort Turbuhaler (budesonide/formoterol) for adult bronchial asthma patients in Japan next January.

Japan Central Medical Insurance Agency Dec. 11 listed the 30- dose device at ¥3,031.6 and ¥6,013.6 for 60 doses. Astellas is co-promoting it with AstraZeneca. The companies estimate ¥560 million in sales for the first three months after launch. Sales are expected to reach ¥29.1 billion in 2017 when it reaches peak sales. (Click here for more - Japanese language)

"Astellas/AstraZeneca To Launch New Drug For Asthma Patients"--CB News (12/14/2009)

Table

View full table

Tags:
Latest Headlines

Xaira Launches With $1bn-Plus And End-To-End AI Strategy

Biogen Sees Improving Momentum In Slow Leqembi Launch

Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative

Day One Springs Into Commercial Action With Ojemda Approval

See All
UsernamePublicRestriction

Register

SC070603

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By